RCM
EW icon

Raleigh Capital Management’s Edwards Lifesciences EW Stock Holding History

Raleigh Capital Management’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.72K Hold
19
– – ﹤0.01% 441
2026
Q1 		$1.52K Buy
+19
New +$1.57K ﹤0.01% 572
2025
Q1 		– Sell
-154
Closed -$11.4K – 717
2024
Q4 		$11.4K Buy
154
+70
+83% +$4.9K ﹤0.01% 588
2024
Q3 		$5.54K Sell
84
-44
-34% -$3.2K ﹤0.01% 687
2024
Q2 		$11.8K Buy
128
+18
+16% +$1.59K 0.01% 540
2024
Q1 		$10.5K Buy
110
+80
+267% +$6.72K ﹤0.01% 552
2023
Q4 		$2.29K Buy
+30
New +$2.09K ﹤0.01% 851
2022
Q3 		– Sell
-44
Closed -$4K – 805
2022
Q2 		$4K Hold
44
– – ﹤0.01% 467
2022
Q1 		$5K Buy
+44
New +$4.94K ﹤0.01% 451

Other funds holding EW

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
DZ Bank
DZ Bank Frankfurt Am Main, Germany $130B AUM 46.38% 1-Year Est. Return
Ninety One (UK)
Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return

Raleigh Capital Management's EW Position: Q2 2026 in Review

Raleigh Capital Management held its Edwards Lifesciences (EW) position steady in Q2 2026 at 19 shares worth $1.72K. The position accounts for ﹤0.01% of the portfolio, ranked #441.

Raleigh Capital Management first reported a position in EW in Q1 2022 and has held it in 9 quarters since. The position peaked at $11.8K in Q2 2024. 1,327 funds tracked by Wall St. Rank hold EW as of Q2 2026.

  • Raleigh Capital Management held 19 shares of Edwards Lifesciences worth $1.72K as of Q2 2026.
  • Raleigh Capital Management left its Edwards Lifesciences share count unchanged in Q2 2026.
  • Edwards Lifesciences made up ﹤0.01% of Raleigh Capital Management's portfolio in Q2 2026, its #441 holding.
  • Raleigh Capital Management first reported a position in Edwards Lifesciences in Q1 2022 and has held it in 9 quarters since.
  • Raleigh Capital Management's Edwards Lifesciences position peaked at $11.8K in Q2 2024.
  • 1,327 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2026.

Based on Raleigh Capital Management's 13F filing for Q2 2026, filed 21 Jul 2026.